Company: United Therapeutics Corporation

Bloomberg ticker: UTHR US

Market cap: US$12,777m

Background: United Therapeutics Corporation develops pharmaceuticals to treat vascular diseases such as pulmonary hypertension and peripheral vascular disease. The Company’s lead products are stable synthetic forms of prostacyclin and are delivered orally or subcutaneously.

World Class Benchmarking of United Therapeutics Corp

---

---

 

• Profitable Growth rank of 1 was up compared to the prior period’s 2nd rank
• This is World Class performance compared to 380 large Health Care companies worldwide
• Profitability rank of 1 was better than its Growth rank of 3
• Profitability rank of 1 was the same compared to the prior period’s 1st rank
• This is World Class performance compared to peers
• Growth rank of 3 was up compared to the prior period’s 4th rank
• This is above average performance compared to peers

 

---

DISCLAIMER: This content is for information purposes only. It is not intended to be investment advice. Readers should not consider statements made by the author(s) as formal recommendations and should consult their financial advisor before making any investment decisions. While the information provided is believed to be accurate, it may include errors or inaccuracies. The author(s) cannot be held liable for any actions taken as a result of reading this article.